| Literature DB >> 33276506 |
Tanaya Walimbe1, Alyssa Panitch1,2.
Abstract
Collagen, the most abundant protein in mammals, has garnered the interest of scientists for over 50 years. Its ubiquitous presence in all body tissues combined with its excellent biocompatibility has led scientists to study its potential as a biomaterial for a wide variety of biomedical applications with a high degree of success and widespread clinical approval. More recently, in order to increase their tunability and applicability, collagen hydrogels have frequently been co-polymerized with other natural and synthetic polymers. Of special significance is the use of bioactive glycosaminoglycans-the carbohydrate-rich polymers of the ECM responsible for regulating tissue homeostasis and cell signaling. This review covers the recent advances in the development of collagen-based hydrogels and collagen-glycosaminoglycan blend hydrogels for biomedical research. We discuss the formulations and shortcomings of using collagen in isolation, and the advantages of incorporating glycosaminoglycans (GAGs) in the hydrogels. We further elaborate on modifications used on these biopolymers for tunability and discuss tissue specific applications. The information presented herein will demonstrate the versatility and highly translational value of using collagen blended with GAGs as hydrogels for biomedical engineering applications.Entities:
Keywords: alginate; chondroitin sulfate; collagen; glycosaminoglycans; heparin; hyaluronic acid; hydrogels; tissue engineering
Year: 2020 PMID: 33276506 PMCID: PMC7711789 DOI: 10.3390/bioengineering7040156
Source DB: PubMed Journal: Bioengineering (Basel) ISSN: 2306-5354
Figure 1Structure of collagen. The amino acid sequence of collagen consists of Gly-Xaa-Yaa repeats, with Xaa and Yaa commonly occupied by proline and hydroxyproline. This unique sequence allows collagen to form an α helix secondary structure. Fibrillar collagen is a triple helix containing crosslinks formed through the action of lysyl oxidase. In vivo, these collagen fibrils form fibers with varying thickness and a D-banding pattern of 67 nm. Made using Biorender.
Figure 2Chemical crosslinking of collagen. Crosslinks are primarily introduced in collagen by targeting carboxylic acid groups on Asp and Glu residues, or amines on Lys, Hyl, and Arg groups (A–D) show some common crosslinkers used to modify collagen.
Figure 3Structures of glycosaminoglycans (GAGs). Disaccharide monomer repeats of glucuronic acid (GlcA) or its epimer iduronic acid (IdoA), and N-acetylgalactosamine (GalNAc) or N-acetylglucosamine (GlcNAc) form the backbone of GAGs, except alginate, which is a GAG analog with GlcA and mannuronic acid repeats. Chondroitin sulfate and heparin are post-translationally sulfated and contain SO3− groups on some disaccharide units.
Examples of collagen-based hydrogels and their applications.
|
| |||
|
|
|
|
|
| Collagen type I | 3 mg/mL, 37 °C | 3D test bed for drug testing | [ |
| 3D tumor model | [ | ||
| Stem cell differentiation | [ | ||
| Electrochemically or magnetically aligned collagen | 7 mg/mL, 37 °C | Tendon tissue engineering | [ |
| Cartilage tissue engineering | [ | ||
| Corneal tissue engineering | [ | ||
| Neural tissue engineering | [ | ||
| Collagen type I and/or type II | 4 mg/mL, 37 °C | Cartilage tissue engineering | [ |
| Concentrated/compressed collagen | 2 mg/mL, 10 mg/mL, | Dermal tissue engineering | [ |
|
| |||
|
|
|
|
|
| EDC crosslinked collagen | 6.33 mg/mL, 4 °C | Corneal tissue engineering | [ |
| Genipin crosslinked collagen | 2 mg/mL, 37 °C | Cartilage tissue engineering, stem cell differentiation | [ |
| Dehydrothermal or UV crosslinked collagen | Unknown; | Vascular tissue engineering | [ |
| Tendon tissue engineering | [ | ||
| Thiol crosslinked collagen | 1% wt/v, 37 °C | Cardiovascular tissue engineering | [ |
| Liver regeneration | [ | ||
| Skin tissue engineering | [ | ||
|
| |||
|
|
|
|
|
| Sulfated HA–collagen | 1 mg/mL, 37 °C | Vascular tissue engineering | [ |
| Skin tissue engineering | [ | ||
| Bone tissue engineering | [ | ||
| Thiolated HA–collagen IPN | 4 mg/mL, 37 °C | Vocal fold tissue engineering | [ |
| HA hydrazine, HA aldehyde–collagen IPN | 2.5 mg/mL, 37 °C | Mimic in vivo microenvironment | [ |
| Photocrosslinked HA–collagen IPN | 3 mg/mL, 37 °C | Regenerative medicine | [ |
| Neural tissue engineering | [ | ||
| EDC crosslinked HA–collagen | 0.5 wt%, 1 wt% | Stem cell differentiation | [ |
| Cartilage tissue engineering | [ | ||
| Dermal tissue engineering | [ | ||
| Corneal tissue engineering | [ | ||
| HA aldehyde–aminooxy PEG-collagen | 50, 100, 200 μg/mL | Neural tissue engineering | [ |
| AAD modified HA-collagen | 8 mg/mL, 25 °C | Cartilage tissue engineering | [ |
|
| |||
|
|
|
| |
| Photocrosslinked CS–collagen IPN | 5 mg/mL, 37 °C | Cartilage tissue engineering | [ |
| Dehydrothermal crosslinked CS–collagen | 2.6 mg/mL, 25 °C | Cartilage and dermal tissue engineering | [ |
| Genipin crosslinked CS–collagen | 1 mg/mL, 37 °C | Cartilage tissue engineering | [ |
| EDC crosslinked CS–collagen | 2.5 mg/mL | Dermal tissue engineering | [ |
| Cartilage tissue engineering | [ | ||
| Neural tissue engineering | [ | ||
| Non crosslinked CS–collagen | 4 mg/mL, 37 °C | Cartilage tissue engineering | [ |
|
| |||
|
|
|
|
|
| Non crosslinked Heparin-collagen | 4 mg/mL, 25 °C | Vascular tissue engineering | [ |
| EDC crosslinked Heparin–collagen | 2.5 mg/mL, 37 °C | Bone tissue engineering | [ |
| starPEG–heparin–collagen | unknown | Cell instruction and differentiation | [ |
|
| |||
|
|
|
|
|
| CaCl2 crosslinked alginate–collagen IPN | 3 mg/mL, 37 °C | 3D tumor model | [ |
| Neural tissue engineering | [ | ||
| Vocal fold tissue engineering | [ | ||
| Cartilage tissue engineering | [ | ||
| Corneal tissue engineering | [ | ||